Edgewise Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$191.4M | -$158.8M | -$114.4M | -$71.7M | -$43.2M |
| Operating expenses | $191.4M | $158.8M | $114.4M | $71.7M | $43.2M |
| Cash from operations | -$143.8M | -$109.0M | -$91.9M | -$52.6M | -$33.5M |
| Capital expenditure | $256,000 | $1.3M | $5.7M | $5.5M | $668,000 |
| Free cash flow | -$144.1M | -$110.3M | -$97.7M | -$58.2M | -$34.2M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $552.6M | $486.8M | $340.0M | $367.1M | $285.2M |
| Total liabilities | $30.3M | $27.6M | $21.2M | $20.4M | $10.8M |
Shares outstanding 107.6M · Free float 75.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.